Polina Selkova

Polina Selkova

Auto-generated profile, based on publicly available information

Polina Selkova

Complex of NBICS Technologies, National Research Center “Kurchatov Institute

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
IFIana Fedorova
Iana Fedorova
AAAnatolii Arseniev
Anatolii Arseniev
PSPolina Selkova
Polina Selkova
GPGeorgii Pobegalov
Georgii Pobegalov
IGIgnatiy Goryanin
Ignatiy Goryanin
KSKonstantin Severinov
Konstantin Severinov
Type II CRISPR–Cas9 RNA-guided nucleases are widely used for genome engineering. Type II-A SpCas9 protein from Streptococcus pyogenes is the most investigated and highly used enzyme of its class. Nevertheless, it has some drawbacks, including a relatively big size, imperfect specificity and restriction to DNA targets flanked by an NGG PAM sequence. Cas9 orthologs from other bacterial species may provide a rich and largely untapped source of biochemical diversity, which can help to overcome the limitations of SpCas9. Here, we characterize CcCas9, a Type II-C CRISPR nuclease from Clostridium cellulolyticum H10. We show that CcCas9 is an active endonuclease of comparatively small size that recognizes a novel two-nucleotide PAM sequence. The CcCas9 can potentially broaden the existing scope of biotechnological applications of Cas9 nucleases and may be particularly advantageous for genome editing of C. cellulolyticum H10, a bacterium considered to be a promising biofuel producer.

21 June 2020 in RNA Biology
Verified
Journal Article
Open access
PSPolina Selkova
Polina Selkova
AVAleksandra Vasileva
Aleksandra Vasileva
GPGeorgii Pobegalov
Georgii Pobegalov
OMOlga Musharova
Olga Musharova
AAAnatolii Arseniev
Anatolii Arseniev
IFIana Fedorova
Iana Fedorova
Cas12e proteins (formerly CasX) form a distinct subtype of Class II type V CRISPR-Cas effectors. Recently, it was shown that DpbCas12e from Deltaproteobacteria and PlmCas12e from Planctomycetes can introduce programmable double-stranded breaks in mammalian genomes. Thus, along with Cas9 and Cas12a Class II effectors, Cas12e could be harnessed for genome editing and engineering. The location of cleavage points in DNA targets is important for application of Cas nucleases in biotechnology. DpbCas12e was reported to produce extensive 5ʹ-overhangs at cleaved targets, which can make it superior for some applications. Here, we used high throughput sequencing to precisely map the DNA cut site positions of DpbCas12e on several DNA targets. In contrast to previous observations, our results demonstrate that DNA cleavage pattern of Cas12e is very similar to that of Cas12a: DpbCas12e predominantly cleaves DNA after nucleotide position 17–19 downstream of PAM in the non-target DNA strand, and after the 22nd position of target strand, producing 3–5 nucleotide-long 5ʹ-overhangs. We also show that reduction of spacer sgRNA sequence from 20nt to 16nt shifts Cas12e cleavage positions on the non-target DNA strand closer to the PAM, producing longer 6–8nt 5ʹ-overhangs. Overall, these findings advance the understanding of Cas12e endonucleases and may be useful for developing of DpbCas12e-based biotechnology instruments.

11 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
PSPolina Selkova
Polina Selkova
AVAleksandra Vasileva
Aleksandra Vasileva
AAAnatolii Arseniev
Anatolii Arseniev
MAMarina Abramova
Marina Abramova
OMOlga Musharova
Olga Musharova
KSKonstantin Severinov
Konstantin Severinov
Type II CRISPR-Cas9 RNA-guided nucleases are commonly used for genome engineering. To date, all characterized Cas9-based genome editors, including the widely used SpCas9, have limitations such as their relatively large size and restriction of targets flanked by a specific PAM sequence. Here, we biochemically characterized more compact SpCas9 ortholog, SuCas9, from Streptococcus uberis , a bacterium inhabiting the mammary glands of dairy cattle. SuCas9 recognizes a novel 5′-NNAAA-3′ PAM, efficiently cleaves DNA in vitro , and is active in human cells. The study of SuCas9 has the potential to expand the range of applications of CRISPR-Cas9 enzymes in medicine and biotechnology.